Cingulate Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CING Nasdaq 2830 www.cingulate.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cingulate Inc.

Final Study Completed for Cingulate’s Lead Asset CTx-1301 - Jan 7th, 2025 12:30 pm
Cingulate Inc Secures $5M Financing for Strategic Growth - Dec 24th, 2024 12:57 pm
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - Dec 23rd, 2024 12:30 pm
CING: Third Quarter Results - Nov 12th, 2024 8:15 am
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - Nov 7th, 2024 12:30 pm
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - Oct 8th, 2024 7:15 pm
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 - Sep 12th, 2024 12:30 pm
Cingulate to Participate in Benzinga All Live Access Event - Aug 27th, 2024 8:30 pm
CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage - Aug 26th, 2024 9:41 am
Cingulate Announces Adjournment of Special Meeting - Aug 23rd, 2024 8:45 pm
Top Midday Decliners - Aug 19th, 2024 6:34 pm
Top Midday Gainers - Aug 15th, 2024 5:49 pm
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD - Aug 15th, 2024 11:45 am
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved - Aug 13th, 2024 11:45 am
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds - Jun 28th, 2024 1:15 pm
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event - Jun 25th, 2024 8:30 pm
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance - Jun 25th, 2024 1:20 pm
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD - May 21st, 2024 1:00 pm
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update - May 8th, 2024 11:00 am
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access - Apr 30th, 2024 9:45 am